Cost-Benefit estimation of cadaveric kidney transplantation, the case of a developing country.
Introduction
Kidney transplantation is nowadays the treatment of choice for end stage renal disease. Refinements in immunosuppression and care of severely ill patients have resulted in a significant improvement in graft survival and quality of life over dialysis [1] .
Dialysis expenditures in turn represent an important part of healthcare system budgets in many countries. For example, in 2006, expenditures in dialysis in Chile were near US$ 160 million, while 1800 people were officially in waiting list for a kidney transplant [2] . So, in a developing country with limited resources it is valuable to determine whether an important contribution could be made by increasing kidney donation and hence transplantation.
We try to address this issue in Chile, where cadaveric donation rates have been constantly low. In fact, as an investment threshold, that is, the maximum value that authorities should be willing to invest in order to increase organ donation rates in the first case. Cost savings from living donation, in turn, are interpreted as the maximum payment that should be given to a living donor in order to induce his/her donation.
All these papers also suggest that there is a substantial improvement in quality of life for kidney recipients, measured as the Quality Adjusted Life Years (QALYs) gained [1] .
In this paper, we perform the exercise of calculating these net benefits using Markov processes like the studies mentioned above, in a developing country, Chile.
Methododology
We developed a Markov model similar to the one used in previous studies [8, 9] in order to estimate the net present value of cumulative costs for both alternative treatments: transplantation and dialysis, and an approximation of the improvement in quality of life, measured as life years gained weighted by a quality factor, which results in Quality Adjusted Life Years (QALYs). This type of model is broadly used in medical related literature for a large number of problems and decision making analysis [11, 12, 13, 14,
15].
Briefly, these models typically assume that, at any point in time, a patient is in one of a finite number of health states and that, from one period to the next, he/she can shift to another health state with a known probability (transition probability). Any health state is then assigned a utility and/or financial cost, and the evaluation of the Markov process gives an expected present value of utility and/or financial costs for a given time horizon [16] .
We compare expected utility and financial costs associated with two alternatives: one in which the patient gets a transplant in the first period and the other in which the same patient does not get a transplant in any period. We consider one-year cycles and a time horizon of 20 years.
In addition, given the nature of the data, we find necessary to consider -as opposed to the studies cited above-the fact that there is a certain degree of uncertainty in some of the parameters used in the model. To do so, we assume some distribution for these parameters and use Montecarlo simulations to obtain a 95% confidence interval for our results. This, in our view, represents a better approximation to real policy-makers' decisions than estimating just a mean value.
Data
Data for parameters used in the model are presented in table1. Survival rates were obtained from the Parameters for which we assumed some degree of uncertainty are, mainly, survival and graft rejection probabilities, obtained from ISP and the literature. We assumed normal distributions truncated at one, with standard deviations equal to 10% of the mean reported in different studies.
Transplantation costs include: immunosuppressive treatment, initial surgery costs, previous studies and follow-up of transplanted patients. Meanwhile, among considered dialysis costs are: hemodialysis, peritoneal dialysis and vascular access.
An important remark is that, as these costs are those effectively considered by the public health-care system because they represent the amounts assigned to each hospital that performs each of those services, we do not consider uncertainty for these values [19] .
We consider one additional assumption that is worth mentioning: Dialysis cost is a weighted average between hemodialysis and peritoneal dialysis costs, in which weights are assigned according to the proportion of patients that use each of these treatments today. Nearly 90% of the population under dialysis was under hemodialysis in Chile at the time of study [20] and we consider substitution towards peritoneal dialysis in our study's time horizon of 20 years until 30% of patients are treated under peritoneal dialysis. We thus consider a constant transition rate of one percentage point per year, to reach that proportion. However, to properly address this estimation, we consider some degree of uncertainty for this transition factor, as presented in table 1.
Results
Estimation results are presented in figures 1 and 2. 
Discussion
Our results indicate that cadaveric renal transplant has a high cost-saving potential for the health-care system in Chile. Previous studies have found similar results for developed economies, like Canada and Germany [8, 9] . This paper uses Markov modelling in order to explore these issues in a developing country and we find that lower transplant costs, relative to dialysis are also present. Although health care costs are considerably less in Chile, the relative benefit of transplantation over dialysis in Chile (21% of dialysis cost saved by transplantation) is similar to that reported in other studies performed with the same methodology in Germany (38%) and Canada (26%). Costs used in this study were obtained in large part from Chilean health authorities and represent what is effectively disbursed by the public health-care system. We try to assess uncertainty regarding some of the parameters used in the model by using Montecarlo simulation which, in our view, is a major contribution to the literature, and we expect to see further development in this sense in the future. These results can rightly be interpreted as an investment threshold for organ donation initiatives that, in our view, could be highly cost-effective in a country with low donation rates, like Chile, as opposed to countries with high donation rates, like Spain, where additional donors can only be reached at significant additional costs. We are confident that this is not the case in Chile, where, in addition to low donation rates, opinion surveys suggest that near 80% of the population is favorable to donation [28].
Specific policies aimed at increasing organ donation rates in Chile are not discussed in this paper, but should be the subject of future research that encompasses specific characteristics of the Chilean reality in transplantation. 
